Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $298.84 (market cap $39.89B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $33.22. Which is the better fit depends on your goals.
| ALNY | TMF | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $491.22 | $44.14 |
52-Week Low | $278.09 | $31.85 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
TMF trades at $33.42, showing minimal daily movement with a slight decline of 0.06%. The technical outlook is bearish with moving averages signaling strong selling pressure, though oscillators remain neutral. Recent news highlights significant long-term underperformance, with a $10,000 investment five years ago now worth approximately $1,527, emphasizing the leveraged ETF's high-risk nature.
The outlook for TMF remains challenging due to its leveraged structure and bearish technical signals. Investment opportunities exist for short-term traders betting on bond market rebounds, but risks include daily leverage decay, interest rate volatility, and the ETF's unsuitability for long-term holdings. Caution is warranted given the amplified loss potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
